Related Experiment Video
Updated: Jun 25, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Sudden death after intravenous administration of a perflutren contrast agent: a case of pseudocomplication?
Haïfa Mahjoub1, Philippe Roméo, Tack-Ki Leung
1Department of Medicine, Montreal Heart Institute, and Université de Montréal, Montreal, QC, Canada.
Abstract:
Perflutren cardiac ultrasound agents improve diagnostic accuracy in patients whose imaging is technically difficult. This report describes a case of sudden death approximately 5 minutes after the intravenous administration of 0.5 mL of perflutren contrast agent (Definity) during transthoracic echocardiography with suboptimal baseline images performed 10 days after coronary artery bypass graft surgery because of hypotension and tachycardia in a 73-year-old patient with severe left ventricular systolic dysfunction. Autopsy did not reveal a clear direct relationship between perflutren and death. This is the first reported case of death related temporally to an echocardiographic contrast agent occurring in Canada and could represent a case of pseudocomplication.
Insights
A rare case of sudden death occurred in Canada after perflutren contrast agent administration during echocardiography. Autopsy found no direct link, suggesting a potential pseudocomplication in cardiac imaging.
Area of Science:
- Cardiology
- Medical Imaging
- Pharmacology
Background:
- Perflutren contrast agents enhance echocardiogram diagnostic accuracy, particularly in challenging cases.
- Transthoracic echocardiography is a key diagnostic tool in cardiology.
Observation:
- A 73-year-old patient experienced sudden death 5 minutes post-intravenous perflutren (Definity) administration.
- The echocardiogram was performed 10 days after coronary artery bypass graft surgery due to hypotension and tachycardia.
- The patient had severe left ventricular systolic dysfunction, and baseline images were suboptimal.
Findings:
- Autopsy examination did not establish a direct causal relationship between perflutren and the patient's death.
- This is the first reported death temporally associated with an echocardiographic contrast agent in Canada.
Implications:
- This case highlights the importance of considering rare adverse events, even without clear causality.
- It may represent a pseudocomplication, emphasizing careful patient selection and monitoring during contrast-enhanced echocardiography.
- Further investigation into the safety profile of perflutren contrast agents in high-risk patients is warranted.
Related Concept Videos
Imaging Studies III: Computed Tomography
Imaging Studies VII: Vascular Imaging
Imaging Studies for Cardiovascular System V: CT
Cardiac Catheterization I: Pre-Procedure Overview
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Imaging Studies for Cardiovascular System III: X-Ray
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...

